COLL Collegium Pharma: רווח נקי למניה ב-12 החודשים האחרונים

Management stability at Collegium Pharmaceutical (COLL) serves as a growth catalyst, as evidenced by the YoY EPS volatility over the last 12 months with the metric standing at -33.80. The business relies on the acquisition of painkiller brands and partnerships with clinics. However, a strictly regulated government market and the expansion of generics create serious challenges, requiring the company to constantly adapt its development strategy.
COLL (Collegium Pharmaceutical): פילוחים אנליטיים ודוחות לפי אינדיקטורים

This indicator tracks the dynamics of the rolling twelve-month net earnings per share, allowing for the identification of market imbalances and the avoidance of purchasing an asset at its peak overheating. By analyzing the rolling year-over-year EPS chart, an investor can assess the resilience of Collegium Pharmaceutical (COLL) to geopolitical disruptions in raw material supplies, which determines the company's actual fundamental reliability.